Checkmate 9ER: A New Arrow in Our Quiver

The results of Phase 3 Checkmate 9ER trial are in! The 9ER trial evaluated the combination of Nivolumab (“Nivo”) and Cabozantinib (“Cabo”). This trial compared the combo to Sunitinib (“Sutent”) in patients who had not previously been on a drug and who had disease that had spread or metastasized.

Nivo is an immunotherapy agent that helps your immune system recognize and mobilize your T-cells to attack the cancer cells. Cabo is a TKI (tyrosine kinase inhibition) drug. The combo improved progression free survival (PFS), meaning the cancer did not progress as quickly compared to the other drug. It also improved OS (overall survival) in patients previously untreated. There were 651 patients in the trial. Nivo and Cabo are each approved by the FDA. This new combo is not yet approved, but will likely be approved in the near future. Other good news is that patient’s toxicity to the drug combo and their quality of life was improved. As soon as this combination is approved, it will give patients another option in their arsenal to battle mRCC.

Read the 2020 ESMO News Release here.

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Dr. Brandon Manley: Physician, Scientist, Advocate

Dr. Brandon Manley: Physician, Scientist, Advocate

Brandon Manley, M.D., is a urologic oncologist who specializes in genitourinary oncology, with a focus on patients with kidney cancer. He currently practices at Moffitt Cancer Center in Tampa, Florida, where he lives with his wife Aimee, and his two daughters Sadie and Brooklyn. The family enjoys...

DISTRICT DAYS 2022 →

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

Dr. Brandon Manley: Physician, Scientist, Advocate

Dr. Brandon Manley: Physician, Scientist, Advocate

Brandon Manley, M.D., is a urologic oncologist who specializes in genitourinary oncology, with a focus on patients with kidney cancer. He currently practices at Moffitt Cancer Center in Tampa, Florida, where he lives with his wife Aimee, and his two daughters Sadie and Brooklyn. The family enjoys...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS
LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

Dr. Brandon Manley: Physician, Scientist, Advocate

Dr. Brandon Manley: Physician, Scientist, Advocate

Brandon Manley, M.D., is a urologic oncologist who specializes in genitourinary oncology, with a focus on patients with kidney cancer. He currently practices at Moffitt Cancer Center in Tampa, Florida, where he lives with his wife Aimee, and his two daughters Sadie and Brooklyn. The family enjoys...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Remembering Ralph: Time Well Spent

Remembering Ralph: Time Well Spent

Ralph Knapp was diagnosed in 2014 with stage IV kidney cancer and used the opportunity to increase research funding and bring hope to patients everywhere. With heavy hearts and profound sadness, we announce the passing of Ralph Knapp, a founder of KidneyCAN and leader of our mission to accelerate...